<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38425">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01812122</url>
  </required_header>
  <id_info>
    <org_study_id>CGMS_SU_Gliptin</org_study_id>
    <nct_id>NCT01812122</nct_id>
  </id_info>
  <brief_title>Effects of Vildagliptine and Glimepiride on Glucose Variability</brief_title>
  <official_title>Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the differences of blood sugar level and glycemic
      variability between sulfonylurea and DPP-4 inhibitor groups applying CGMS for a chosen
      number of type 2 DM patients. The investigators also reveal influences of each drugs on
      cardiovascular risk factors by measuring related biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We enroll patients with type 2 DM with uncontrolled glucose level on Metformin monotherapy
      over 1000mg /day (HbA1C over 7%).

      Before drug administration, we conduct basal lab study including CGMS.  After 3 month of
      random administration of vildagliptin or glimepiride, we check CGMS, glucose levels, CV
      biomarkers, and estimate hypoglycemic index. We replace with the other drug for 3 months,
      and then conduct the same measurements. No wash-out period is necessary since result
      variables are measured after the 3 months of administration for a different drug.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Glycemic variability index</measure>
    <time_frame>before and after 3 months of each drug administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular disease risk factor</measure>
    <time_frame>before and after 3 months of each drug administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>glucose profile and lipid profile</measure>
    <time_frame>before and after 3 months of each drug administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypoglycemic index</measure>
    <time_frame>before and after 3 months of each drug administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting with Glimepiride. After 3 month, switching to vildagliptin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting with vildagliptin. After 3 month, switching to Glimepiride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_label>Vildagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_label>Vildagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  with type 2 DM

          -  with uncontrolled glucose level on Metformin monotherapy over 1000mg /day (HbA1C over
             7%). Provided that the tolerance for metformin is poor, enrollment of patients with
             lower dose of metfomrin is open.

          -  who have never been prescribed with test drugs, sulfonylurea or DPP-4 inhibitor/GLP-1
             analogue  in 3 months

          -  who can be applied with CGMS

        Exclusion Criteria:

          -  who has liver function abnormality or renal function abnormality

          -  who has any kind of diseases, operations, medical treatments that can affect glucose
             levels
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hye Seung Jung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hye Seung Jung, MD</last_name>
    <phone>+82-2-2072-0240</phone>
    <email>jungjhs@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyeong Seon Park, MD</last_name>
      <phone>+82-2-2072-2228</phone>
      <email>yurica514@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hye Seung Jung</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
